

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yechiel Shai et al. Confirmation No.: 8544
Application No.: 10/560,727 Patent No.: 7,671,011 B2
Filing Date: October 10, 2006 Patent Date: March 2, 2010
For: ANTIMICROBIAL AND ANTICANCER Attorney Docket No.: 85189-16300
LIPOPEPTIDES

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is requested that a Certificate of Correction be issued in connection with the above-identified patent correcting the errors listed on the accompanying Form PTO-1050. The corrections requested are as follows.

On the Title page, Item (57) **ABSTRACT**, line 2, change "acid The" to -- acid. The --.

This request is being made pursuant to 37 C.F.R. § 1.323 to correct errors of a clerical or typographical nature and do not involve changes that would constitute new matter or require reexamination. A fee of \$100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,



Allan A. Fanucci, Reg. No. 30,256

Date: June 17, 2010

WINSTON & STRAWN LLP
Customer No. 28765
212-294-3311

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,671,011 B2

Page 1 of 1

APPLICATION NO. : 10/560,727

DATED: : March 2, 2010

INVENTOR(S) : Shai et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Item (57) ABSTRACT, line 2, change "acid The" to -- acid. The --.



US007671011B2

(12) **United States Patent**
Shai et al.

(10) **Patent No.:** US 7,671,011 B2
(45) **Date of Patent:** Mar. 2, 2010

(54) **ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES**(75) Inventors: **Yechiel Shai**, Yehud (IL); **Dorit Avrahami**, Ashdod (IL)(73) Assignee: **Yeda Research & Development Co. Ltd.**, Rehovot (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 327 days.

(21) Appl. No.: **10/560,727**(22) PCT Filed: **Jun. 18, 2004**(86) PCT No.: **PCT/IL2004/000544**§ 371 (c)(1),
(2), (4) Date: **Oct. 10, 2006**(87) PCT Pub. No.: **WO2004/110341**PCT Pub. Date: **Dec. 23, 2004**(65) **Prior Publication Data**

US 2007/0072808 A1 Mar. 29, 2007

Related U.S. Application Data

(60) Provisional application No. 60/479,465, filed on Jun. 19, 2003.

(51) **Int. Cl.****C07K 7/00** (2006.01)(52) **U.S. Cl.** **514/2; 530/327; 530/328**(58) **Field of Classification Search** **514/2; 530/329, 330, 331, 327, 328**
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

3,817,973 A *	6/1974	Bouchaudon et al.	530/319
5,583,198 A	12/1996	Whittaker	530/345
5,837,249 A	11/1998	Heber-Katz et al.	424/186.1
5,871,746 A	2/1999	Boutillon et al.	424/208.1
6,011,008 A	1/2000	Domb et al.	514/8
6,011,013 A	1/2000	Carr et al.	514/13
6,172,038 B1	1/2001	Shai et al.	514/2
6,183,736 B1	2/2001	Moyné et al.	424/93.462
6,384,013 B1	5/2002	Burkhardt et al.	514/11
6,794,490 B2 *	9/2004	Hill et al.	530/317
7,262,268 B2 *	8/2007	Morytko et al.	530/317
2002/0077317 A1	6/2002	Das	514/171

FOREIGN PATENT DOCUMENTS

WO	WO98/37090	8/1998
WO	WO02/40529	5/2002

OTHER PUBLICATIONS

Creemer L. C. (J Med Chem. 39(25), 5021-4, 1996).*
 Uehara Y (Journal of Antibiotics 29(9), 937-943, 1976).*
 Schott H (Anti-Cancer Drug Design 11(6), 451-62, 1996).*

Trani A [Farmaco (Societa Chimica Italiana: 1989), 51(7), 503-512, 1996].*

Clark C. R. (J Med Chem. 30(7), 1214-18, 1987).*

Alexander et al., "Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches". Drugs. Nov. 1997;54(5):657-78.

Avrahami et al., "Effect of multiple aliphatic amino acids substitutions on the structure, function, and mode of action of diastereomeric membrane active peptides". Biochemistry Oct. 23, 2001;40(42):12591-603.

Avrahami et al., "Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity". Biochemistry Feb. 19, 2002; 41(7):2254-63.

Bechinger, "The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy". Biochim Biophys Acta. Dec. 15, 1999;1462(1-2):157-83.

Denning DW. "Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host". J Antimicrob

Chemother. Oct. 1999;28 Suppl B:1-16.

Efron et al., "Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture". J Biol Chem. Jul. 5, 2002;277(27):24067-72. Epub Apr. 5, 2002.

Gavish et al., "Growth inhibition of prostate cancer xenografts by halofuginone". Prostate. May 1, 2002;51(2):73-83.

Groll et al., "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital". J Infect. Jul. 1996;33(1):23-32.

Hong et al., "Structure and organization of hemolytic and nonhemolytic diastereomers of antimicrobial peptides in membranes". Biochemistry. Dec. 21, 1999;38(51):16963-73.

Merrifield, "Solid phase peptide synthesis". J. Am. Chem. Soc. Jan. 31, 1963; 85: 2149-2154.

Minamoto et al., "Fungal infections in patients with acquired immunodeficiency syndrome". Med Clin North Am. Mar. 1997;81(2):381-409.

Oren et al., "Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study". Biochemistry. Feb. 18, 1997;36(7):1826-35.

Oren et al., "A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity". J Biol Chem. Jun. 6, 1997;272(23):14643-9.

Oren et al., "Mode of action of linear amphipathic alpha-helical antimicrobial peptides". Biopolymers. 1998;47(6):451-63.

Papo et al., "A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice". J Biol Chem. Jun. 6, 2003;278(23):21018-23. Epub Mar. 19, 2003.

(Continued)

Primary Examiner—David Lukton**(74) Attorney, Agent, or Firm**—Winston & Strawn LLP(57) **ABSTRACT**

Lipophilic conjugates comprise a peptide coupled to a fatty acid. The peptide comprises at least two positively charged amino acid residues; the peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.